GDI2-IN-1

• UNSPSC Description:

  GDI2-IN-1 (compound (+)-37) is a GDP-dissociation inhibitor beta (GDI2) inhibitor with an IC50 of 2.87 μM and a KD of 36 μM. GDI2-IN-1 exhibits excellent in vivo antitumor activity in GDI2-overexpressing pancreatic xenograft models[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/gdi2-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@](C[C@@H]1C)(CC2=CN(CC3=CC=C(F)C=C3)N=N2)C[C@@]4([H])N1CCC5=C4C=C(OCC6=CC(C)=CC(C)=C6)C(OCC7=CC(C)=CC(C)=C7)=C5

• Molecular Weight:

  674.85

• References & Citations:

  [1]Yong Sun, et al. Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy. JACS Au 2023, September 26, 2023.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported